Gold prices cool after hitting over 2-week high on Fed independence fears
In a recent transaction reported on June 6, 2025, Thomas Brian C., the Chief Executive Officer of Metagenomi, Inc. (NASDAQ:MGX), sold 10,785 shares of the company’s common stock. The shares were sold at a price of $1.75 each, totaling $18,873. Following this transaction, Brian retains ownership of 2,517,491 shares. The sale comes amid a challenging period for MGX, with the stock down over 70% in the past year. According to InvestingPro analysis, the company appears undervalued at current levels.
This sale was conducted to satisfy tax withholding obligations related to the vesting of restricted stock units granted to Brian in April 2024. It is important to note that this transaction was not a discretionary trade by the CEO but rather an automatic sale for tax purposes. InvestingPro data shows management has been actively buying back shares, while maintaining a strong balance sheet with more cash than debt. Discover 10+ additional insights and detailed financial metrics with an InvestingPro subscription.
In other recent news, Metagenomi has made a significant breakthrough in gene editing technology, as reported in Nature Communications. The company has developed a compact CRISPR-associated transposase (CAST) system that successfully integrates large, therapeutically relevant genes into the human genome. This advancement could potentially revolutionize the treatment of complex genetic diseases like Wilson’s disease and cystic fibrosis. In addition, H.C. Wainwright has adjusted its outlook on Metagenomi, reducing the 12-month price target from $14 to $7 while maintaining a Buy rating. This revision comes amid heightened regulatory uncertainties following recent changes at the U.S. Food and Drug Administration. The departure of Dr. Peter Marks from the FDA is seen as a factor that may increase the hurdles for approving genetic medicines, prompting H.C. Wainwright to raise its discount rate for Metagenomi to 14%. Despite these challenges, the analyst firm still holds a positive outlook on Metagenomi’s potential. The company’s recent technological advancements are expected to pave the way for further developments in precision genetic medicines.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.